GlobeNewswire

Leading the industry: Excel Dryer is the first hand dryer manufacturer to publish third-party, verified Environmental Product Declarations (EPDs)

Dela

High-speed, energy-efficient XLERATOR®, XLERATOReco® and ThinAir® Hand Dryers evaluated and proven to be sustainable

 

EAST LONGMEADOW, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Excel Dryer, Inc., today announced that three of their hand dryers, the original, patented, high-speed, energy-efficient XLERATOR® Hand Dryer, the XLERATOReco® Hand Dryer and the ThinAir® Hand Dryer, were evaluated, and their environmental claims, substantiated with the publication of the hand dryer industry's first Environmental Product Declarations (EPDs) by UL Environment, a business division of Underwriters' Laboratories. An Environmental Product Declaration is a standardized way of quantifying the environmental impact of a product by studying the raw materials and energy consumption during its production, use and disposal. For buyers and specifiers, the EPDs are a disclosure tool that helps purchasers better understand a product's sustainable qualities and environmental repercussions so they can make more informed product selections.

To create an EPD, there must first exist Product Category Rules (PCR) which create testing guidelines and reporting methods through industry consensus, thereby permitting buyers and specifiers to compare products, apples-to-apples. The corresponding EPDs provide insight on the environmental impact of products from cradle-to-grave. Last year, UL Environment selected Excel Dryer to chair a committee comprised of leading hand dryer manufacturers. Working collaboratively, the group created the PCR for hand dryers, a first for the hand dryer industry and the first global standard for any industry.

"I was honored to have been selected as chairman of the PCR committee," explained Vice President of Marketing and Sales, William Gagnon. "Excel Dryer is proud to have been the first to publish dry time and energy use results of our three high-speed hand dryers to the new global PCR standards. We continually challenge ourselves to lead the industry, and when it comes to environmental sustainability, we lead by example."

For a product to gain EPD certification, it must be studied cradle-to-grave by way of a Life Cycle Assessment (LCA) conducted by a credible third-party following ISO 14040 standards. Excel Dryer again called upon world-renowned Quantis International, with whom they previously worked, for their latest LCA.

"Excel Dryer has long-expressed a commitment to environmental sustainability and our credible, third-party testing results quantify and substantiate their claims," said Jon Dettling, U.S. director at Quantis International. "We, at Quantis, are honored to have been chosen to play a part in the historic creation of the first hand dryer Environmental Product Declarations."

Excel Dryer continually leads the industry with firsts including inventing the original patented, XLERATOR Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer was the first hand dryer manufacturer to become a member of the United States Green Building Council (USGBC) and to commission an independent, third-party Life Cycle Assessment of high-speed, energy-efficient hand dryers versus conventional hand dryers and paper towels. Excel hand dryers are the first and only to achieve Made In USA® certification. The publication of EPDs continues Excel Dryer's lists of celebrated accomplishments and ushers the hand dryer industry into a new age of transparency.

"We believe we have again solidified our place as industry leader," explained Excel Dryer President, Denis Gagnon. "Certainly, we recognize the significance of being the first to publish EPDs for our hand dryers but our ultimate goal has always been to see others follow our lead to allow for greater transparency in the market."

Product Manager of Environmental Product Declarations at UL Environment, Anna Nicholson Lasso, lauded the manufacturer. "We applaud the efforts of Excel Dryer who was instrumental in obtaining the consensus that we needed to publish this first-of-its-kind global Product Category Rules for the hand dryer industry," said Nicholson Lasso. "The development and publication of Environmental Product Declarations further demonstrates Excel Dryer's commitment to transparency and encourages other manufacturers to follow suit."

For more information about Excel Dryer or its product line, visit exceldryer.com. For more information about Excel's three, new Environmental Product Declarations, visit: exceldryer.com/epd-leading-the-industry/

About Excel Dryer, Inc.  For over 50 years, Excel Dryer has been manufacturing the finest American made hand dryers featuring the XLERATOR® Hand Dryer. Excel Dryer is a family-owned and -operated company which revolutionized the industry by inventing the patented XLERATOR technology that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer continues to lead the industry with its expanded and enhanced product line featuring adjustable sound, speed and heat controls,  HEPA Filtration System, multi-voltage options and more. Combined with the most complete line of options and accessories, the best hand drying solution can be designed for any restroom environment. Excel Dryer prides itself on offering the ultimate customer service and making dependable products by employees committed to quality and dependability. Excel Dryer products are available through an established network of sales representatives who call on more than 4,000 distributors globally for distribution worldwide. Learn more about Excel Dryer at  exceldryer.com .

Contact: Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fc91ae73-c2df-4ac5-8e6b-1cc5004b6dc3




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Excel Dryer Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum